<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Bristol Myers Squibb & Co (NYSE: BMY) has announced interim results from the True North open-label extension study evaluating the long-term efficacy and safety of Zeposia (ozanimod) in active ulcerative colitis (UC). Findings show that the percentage of patients achieving clinical remission, clinical response, endoscopic improvement, and corticosteroid-free remission was maintained through Week 142.
...read full article on Benzinga
